publications and conference presentations.
evidence informs insight. insight drives impact.
advancing the drug development landscape.
Through the years, we have amassed an extensive clinical database for WEE1 inhibition, which has provided deep insights into optimal dosing, safety management, and therapeutic potential. We continue to follow the data and publish our findings to share what we’ve learned, enable collaboration across the oncology community, and accelerate progress for patients.
featured publications.
PUBLICATION
Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer
PUBLICATION
Azenosertib in Combination With Bevacizumab as Maintenance Therapy in Patients With Advanced Ovarian Cancer: Part 2 of a Phase 1b study (MUIR/ZN-c3-002)
PUBLICATION
Cyclin E1 is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer (PROC): Outcomes From Part 1b of the DENALI Study (GOG-3066)